Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas by unknown
Sriram et al. BMC Cancer 2012, 12:428
http://www.biomedcentral.com/1471-2407/12/428RESEARCH ARTICLE Open AccessPleural fluid cell-free DNA integrity index to
identify cytologically negative malignant pleural
effusions including mesotheliomas
Krishna B Sriram1,2*, Vandana Relan1,2, Belinda E Clarke3, Edwina E Duhig3, Morgan N Windsor4, Kevin S Matar4,
Rishendran Naidoo4, Linda Passmore1,2, Elizabeth McCaul1,2, Deborah Courtney1,2, Ian A Yang1,2,
Rayleen V Bowman1,2 and Kwun M Fong1,2Abstract
Background: The diagnosis of malignant pleural effusions (MPE) is often clinically challenging, especially if the
cytology is negative for malignancy. DNA integrity index has been reported to be a marker of malignancy. The aim
of this study was to evaluate the utility of pleural fluid DNA integrity index in the diagnosis of MPE.
Methods: We studied 75 pleural fluid and matched serum samples from consecutive subjects. Pleural fluid and
serum ALU DNA repeats [115bp, 247bp and 247bp/115bp ratio (DNA integrity index)] were assessed by real-time
quantitative PCR. Pleural fluid and serum mesothelin levels were quantified using ELISA.
Results: Based on clinico-pathological evaluation, 52 subjects had MPE (including 16 mesotheliomas) and 23 had
benign effusions. Pleural fluid DNA integrity index was higher in MPE compared with benign effusions (1.2 vs. 0.8;
p<0.001). Cytology had a sensitivity of 55% in diagnosing MPE. If cytology and pleural fluid DNA integrity index
were considered together, they exhibited 81% sensitivity and 87% specificity in distinguishing benign and
malignant effusions. In cytology-negative pleural effusions (35 MPE and 28 benign effusions), elevated pleural fluid
DNA integrity index had an 81% positive predictive value in detecting MPEs. In the detection of mesothelioma, at a
specificity of 90%, pleural fluid DNA integrity index had similar sensitivity to pleural fluid and serum mesothelin
(75% each respectively).
Conclusion: Pleural fluid DNA integrity index is a promising diagnostic biomarker for identification of MPEs,
including mesothelioma. This biomarker may be particularly useful in cases of MPE where pleural aspirate cytology
is negative, and could guide the decision to undertake more invasive definitive testing. A prospective validation
study is being undertaken to validate our findings and test the clinical utility of this biomarker for altering clinical
practice.
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Pleural effusions can be caused by a diverse array of
pleural, pulmonary or extrapulmonary diseases [1,2]. An
important diagnosis to be established or excluded is ma-
lignancy, particularly in unilateral pleural effusions.
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reproduction in any medium, provided the orworldwide are due to metastases from tumours originat-
ing in the lung and breast or lymphoma. Less com-
monly, MPEs are due to mesothelioma, which usually
arises after a long latent period after exposure to asbes-
tos fibres. The median survival of patients with MPEs is
only 4-10 months after clinical diagnosis. Consequently,
expert guidelines recommend that when investigating
pleural effusions, a minimum number of tests be per-
formed while aiming to achieve a swift diagnosis [3]. Al-
most all patients with unilateral pleural effusions
undergo pleural fluid aspiration and cytology. WhileLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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detection of tumour cells in pleural fluid [4], its sensitiv-
ity varies between 30% for mesothelioma to up to 60%
for adenocarcinoma [5,6].
Recently, soluble mesothelin-related peptide (or
mesothelin), has been approved by the U.S. Food and
Drug Administration for the diagnosis and monitoring of
mesothelioma. Mesothelin is a glycoprotein overexpressed
by mesothelioma and measurements in pleural fluid and
serum are significantly higher compared to non-
mesothelioma MPEs and benign effusions [7,8]. While
pleural fluid and serum mesothelin are diagnostic biomar-
kers for mesothelioma, a similar biomarker for non-
mesothelioma MPEs may have considerable clinical utility.
Cell-free DNA (cfDNA) is a macromolecule that can
be readily detected in biological fluids and is believed to
be released from either apoptotic or necrotic cells [9].
Necrosis, which occurs in malignant tumours typically
generates a spectrum of DNA fragments with varying
strand lengths due to random and incomplete digestion
of genomic DNA by deoxyribonucleases [10]. In con-
trast, cell death in normal nucleated blood cells occurs
predominantly via apoptosis resulting in the production
of uniform small DNA fragments (<200bp) [11]. The
DNA integrity index, measured as the ratio of longer to
shorter DNA fragments, has been shown to be higher in
the plasma and serum of patients with solid organ ma-
lignancies compared to normal individuals [12]. Hence,
the measurement of DNA integrity index in biological
fluids has promise as a minimally invasive diagnostic
biomarker for malignancy. To the best of our knowledge,
the utility of DNA integrity in diagnosing MPE and spe-
cifically mesothelioma has not been compared to pleural
fluid cytology and mesothelin.
In this study, we measured DNA fragments by real-
time quantitative polymerase chain reaction (PCR) on 75
matched pleural fluid and serum samples. We chose to
measure ALU sequences since they are the most abun-
dant repetitive sequences accounting for more than 10%
of the genome. Our primary objective was to determine
if pleural fluid and/or serum DNA integrity could serveLog concentration (ALU115)
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Figure 1 Standard curves of ALU 115bp and 247bp amplicons. DNA fr
and used to construct the standard curves from which the quantity of DNAas a diagnostic biomarker for MPEs, particularly where
cytological examination is negative and clinical suspicion
remains. A secondary objective of the study was to com-
pare DNA integrity index to mesothelin levels measured
by ELISA assay in pleural fluid and serum for diagnosis
of mesothelioma.Methods
Subjects and sample collection
We recruited 75 consecutive subjects with undiagnosed
pleural effusions referred to The Prince Charles Hospital
(Brisbane, Australia) between February 2010 and Sep-
tember 2011. All study subjects provided written
informed consent. The study was approved by the
Human Research Ethics Committees at The Prince
Charles Hospital (TPCH) and The University of
Queensland. Pleural fluid was collected during simple
thoracocentesis, performed during the diagnostic work-
up of patients with pleural effusions or prior to tube
thoracostomy, or a surgical thoracoscopic procedure. In
all but one subject, pleural fluid obtained at the time of
the first thoracocentesis was used for analysis. The
pleural fluid was transferred within 24 hours to the la-
boratory in polystyrene containers without anticoagulant
(SARSTEDT, Nümbrecht, Germany) at room
temperature. The pleural fluid samples were centrifuged
for 7 minutes at 600g and supernatants stored in 1ml ali-
quots at -80°C for DNA extraction and ELISA experi-
ments. Matched blood samples were also collected
within 24 hours of obtaining pleural fluid. Serum was
separated by centrifuging the blood samples for 10 min-
utes at 1700g and stored at -20°C for DNA extraction
and ELISA experiments. Two mL of pleural fluid and
serum were used for DNA extraction using Nucleospin
kits (Machery-Nagel, DÜREN, Germany) following the
manufacturer’s instructions. DNA was eluted in 100μL
TE buffer and stored at -80°C until use. Mesothelin
ELISA assays were performed on pleural fluid super-
natant and serum aliquots stored at -80°C and -20°C re-
spectively, then allowed to thaw to room temperature.Log concentration (ALU247)
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om female genomic DNA was serially diluted (from 10ng to 0.1ng)
of the patients was calculated.
Figure 2 Melting curves of ALU 115bp and ALU 247bp
amplifications signals from 20 patients. Following amplification,
melting curves were obtained by calculating the derivatives dF/dT
vs. temperature. ALU 115bp primers produce a peak of
approximately 83°C and ALU 247bp at approximately 86°C.
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Quantification of DNA fragments was performed by quan-
titative real-time PCR (qPCR) of ALU 115bp and 247bp
repeats as previously published [13]. The sequences of the
ALU 115bp primers were as follows: forward: 50-CCT-
GAGGTCAGGAGTTCGAG-30 and reverse: 50-CCCGA-
GTAGCTGGGATTACA-30; ALU 247bp primers were
forward: 50-GTGGCTCACGCCTGTAATC-30 and reverse:
50-CAGGCTGGAGTGCAGTGG-30.
The ALU 115 primer set amplifies both short 115bp
product while the ALU 247 primer set amplified a longer
247bp fragments. The amplicon sizes were confirmed on
gel electrophoresis. Quantification of DNA in each sample
was determined by a standard curve with serial dilutions
(10ng-0.01pg) of commercially available human female
genomic DNA (Promega, Sydney, Australia) (Figure 1).
Standard curves were determined for both ALU 115 and
247 primer sets respectively and the curves were obtained
by putting the concentration log of the standard in x-axis
and the values of the threshold cycles (Ct) in the y-axis.
The quantity of DNA (ng/ml) present in the sample was
extrapolated from the standard curve according to the Ct
value. The DNA integrity index, represented by the ratio of
the longer to shorter (ALU 247bp/ALU 115bp) fragments,
was calculated for each individual sample (pleural effusion
and serum) by dividing the ALU247 DNA quantity (ng/
mL) by the ALU 115 DNA quantity (ng/mL). A negative
control (water template) was performed in each plate. 10ng
of commercially available human female genomic DNA
(Promega, Sydney, Australia) was used as a positive control
in each plate run. The reaction mixture consisted of 1μl of
DNA template, 20μmol/L of the forward and reverse pri-
mers (ALU115 or ALU247), 5μl of QuantiFast mastermix
(Qiagen, Sydney, Australia) in a total reaction volume of
10μl. Real-time PCR amplification was performed with
hold at 95°C for 10 minutes, followed by 35 cycles of 95°C
for 30s and 64°C for 30s, followed by melt curve analysisusing a RotorGene 6000 (Qiagen, Hilden, Germany). The
PCR protocol was optimised to yield optimal results to suit
the equipment, reagents and conditions of our laboratory.
Laboratory personnel performing the qPCR assays were
blinded to the specimen identity. Using the human female
genomic DNA (positive control) we found that the median
intra- and inter-assay coefficient of variation (CV) for
115bp were 4% (IQR, 3%-6%) and 4% (IQR, 3%-4%) re-
spectively. Similarly, the median intra- and inter- assay CV
of human female genomic DNA for the 247bp primers
were 4% (IQR 3%-7%) and 6% (IQR, 5%-7%) respectively.
Melt curve analysis demonstrated that the 115bp amplicon
produced a peak at 83°C and the 247bp amplicon pro-
duced a peak at 86°C (Figure 2).
Mesothelin assay
Pleural fluid and serum mesothelin concentrations were
determined in duplicate using a double-determinant
ELISA assay, the MESOMARK kit (Fujirebio Diagnos-
tics, Malvern, PA, USA), according to the manufacturer’s
instructions. Nanomolar (nM) mesothelin concentra-
tions were determined from a standard curve performed
on each plate. Samples with high (13.5nM, range 10.8-
16.2nM) and low (4.5nM, range: 3.6-5.4nM) mesothelin
concentrations provided in the MESOMARK kit were
run on each plate in duplicate to check inter-assay
reproducibility. The inter-assay and intra-assay CV of
mesothelin concentration of the positive control samples
were 3% (IQ 2%-4%) and 4% (2%-5%) respectively.
Diagnoses of pleural effusions
A definitive diagnosis of the pleural effusion was
obtained by interrogation of the subject’s hospital
records and pathology database. In brief, Light’s criteria
were used to differentiate transudates from exudates
[14]. The effusion was categorized as MPE if the pleural
fluid cytology was positive for malignancy. Subjects with
negative pleural fluid cytology were also deemed to have
MPEs if a tissue biopsy was positive for malignancy or if
subjects had disseminated malignancy and there was no
alternative explanation for the effusion. Benign effusions
were considered to be due to: ‘inflammatory pleuritis’ in
subjects with histologic evidence of pleural inflammation
only; ‘parapneumonic’ in subjects with an exudative effu-
sion and clinical evidence of pneumonia; ‘asbestos
related effusion’ in subjects with asbestos exposure,
pleural plaques and/or rounded atelectasis and no
evidence of mesothelioma; ‘congestive cardiac failure’ in
subjects with transudative effusions and clinical features
of cardiac failure; ‘chronic liver disease’ in a subject with
a transudate effusion and previously diagnosed cirrhosis;
‘pulmonary embolism’ in a subject with an exudative
effusion and demonstration of pulmonary embolism
on computed tomography pulmonary angiogram and
Table 1 Aetiology of pleural effusions
Number of Patients, n(%)
Malignant Pleural Effusions
Lung cancer 22 (42)
Mesothelioma 16 (31)
Breast carcinoma 5 (10)
Lymphoma 3 (6)
Renal cell carcinoma 1 (2)
Melanoma 1 (2)
Peripheral nerve sheath tumour 1 (2)
Solitary fibrous tumour 1 (2)
Prostate carcinoma 1 (2)
Gastric adenocarcinoma 1 (2)
Benign Pleural Effusions
Inflammatory pleuritis 8 (35)
Asbestos related effusions 4 (17)
Parapneumonic 4 (17)
Congestive cardiac failure 4 (17)
Chronic liver disease 1 (4)
Pulmonary embolism 1 (4)
Connective tissue disorder 1 (4)





Range 30 – 94
< 60 years of age 12 (23)




Smoking status, n (%)
Current or Former 33 (63)
Never 19 (37)
Pleural fluid, median (IQR)
Protein, g/L 43.5 (37.0 – 48.0)
LDH, IU/L 390 (198.5 – 926.5)
Glucose, mmol/L 6 (4 -7)
Light’s criteria classification, n (%)
Transudate 5 (10)
Exudate 47 (90)
Pleural fluid cytology, n (%)
Positive for malignancy 29 (56)
Negative for malignancy 23 (44)
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tive effusion and previously diagnosed mixed connective
tissue disorder.
Statistical analysis
The Mann-Whitney U test was used to compare total and
necrotic DNA, integrity index and mesothelin in pleural
fluid and serum between subjects with MPE and those
with benign effusions. Spearman’s rho coefficient was used
to assess correlations between mesothelin values, total
DNA, necrotic DNA and DNA integrity index in serum
and pleural effusions. A receiver operating characteristic
(ROC) curve was performed to determine the area under
the curve, sensitivity and specificity of pleural fluid DNA
integrity index and mesothelin in the pleural fluid and
serum. The area under the ROC curve (AUC) was com-
puted with 95% confidence intervals. All statistical tests
were performed using SPSS Student Version 19 (SPSS
Inc., Chicago, IL, USA) and results were considered sig-
nificant at p <0.05 (two-tailed).
Results
Subject characteristics
Based on clinical and pathological review, 52 study sub-
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ALU 115 (ng/ml) p-value 0.217 0.509 0.147 0.526
Mean, Range 1841.6 1512.2 2065.0 1836.6 1616.7
(21.8-6328.7) (41.7 – 5964.2) (21.8 – 6204.8) (176.5 – 6328.7) (48.5 – 7814.9)
Median (IQR 25-75) 963.9 712.3 1366.5 723.5 520.3
(411.1-2385.7) (502.3 – 1992.9) (488.4 – 2624.0) (299.1 – 4492.1) (128.6 – 2481.9)
ALU 247 (ng/ml) p-value 0.066 0.187 0.061 0.231
Mean, Range 2065.7 1827.6 1947.8 2694.1 1389.4
(23.5 – 9973.7) (23.5 – 7220) (71.5 – 6671.4) (151.7 – 9973.7) (8.2 – 7126)
Median (IQR 25-75) 1186.2 1047.8 1368.0 1060.4 371.8
(397.7 – 2616.5) (580.7 – 2353.7) (346.9 – 2660.3) (267.4 – 6894.9) (85.5 – 2036.6)
DNA integrity index p-value <0.001 <0.001 0.018 <0.001
Mean, Range 1.2 1.2 1.09 1.25 0.8
(0.4 – 3.3) (0.6 – 1.9) (0.4 – 3.3) (0.6 – 1.8) (0.0 – 1.5)
Median (IQR 25-75) 1.1 1.2 0.9 1.3 0.8
(0.8 – 1.5) (0.9 – 1.6) (0.7 – 1.2) (0.9 – 1.6) (0.7 – 0.9)
Mesothelin, nM p-value 0.242 <0.001 0.533 0.132
Mean, Range 36.9 104.2 8.0 5.5 7.4
(1-392) (4 – 392) (1-31) (0.7 – 24.5) (1- 36)
Median (IQR 25-75) 6.06 38.0 4.6 3.1 4.6
(3.1 – 19.0) (10.8 – 106.5) (3 – 11.7) (1.8 – 8.4) (2.6 – 8.4)
*p-value-Mann-Whitney U test comparing diagnoses with benign effusions.
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gies of MPE were lung cancer (n=22), mesothelioma
(n=16), breast cancer (n=5) and lymphoma (n=3), while
the most common aetiologies for benign effusions were
inflammatory pleuritis (n=8), asbestos related effusions
(n=4), parapneumonic effusions (n=4) and congestive
cardiac failure (n=4) (Table 2). The clinico-pathological
characteristics of the study subjects are listed in Table 2.
The median age of the MPE and benign effusions sub-
jects was 68 years and 73 years respectively. There were
no differences in the characteristics of patients between
MPE and benign effusions. Male subjects comprised
60% of the MPE group compared to 74% in the benign
effusion group. Pleural fluid cytology analysis identified
malignant cells in twenty-nine patients (56%). Among
the remaining 23 patients with MPEs, the diagnosis was
established by pleural biopsy in 16 patients. For the
remaining seven patients, the treating clinician deter-
mined the pleural effusion to be malignant in the con-
text of disseminated malignancy. Five patients with
transudate effusions were determined to be MPEs, of
which 1 patient was cytology positive while the
remaining four disseminated malignancy.Quantification of cell-free DNA fragments
Pleural Fluid
Pleural fluid DNA fragment analysis for MPE and be-
nign effusions are provided in Table 3. There was no dif-
ference between MPE and benign effusions in the
pleural fluid ALU 115 (median, 963.9 ng/mL vs. 520.3
ng/mL, p=0.217) (Figure 3a), or ALU 247 (median,
1186.2 ng/mL vs. 371.8 ng/mL, p=0.066) (Figure 3b).
However the DNA integrity index was higher in the
MPEs compared to benign effusions (median, 1.1 vs. 0.8,
p<0.001) (Figure 3c). Furthermore DNA integrity index
was higher than benign effusions in all subgroups of
MPE, i.e. mesothelioma (median, 1.2 vs. 0.8, p<0.001),
lung cancer (median, 1.09 vs. 0.8, p=0.018) and other
metastatic cancers (median, 1.3 vs. 0.8, p<0.001).
In cytology negative subjects eventually diagnosed with
MPE (n=23), the DNA integrity index was significantly
higher compared with that of subjects with benign effu-
sions (median, 1.08 vs. 0.8, p<0.001).
Median pleural fluid DNA integrity index was not sig-
nificantly different according to gender, smoking, pleural
fluid biochemical or cytology classification in these sub-
jects (Table 4).
























































































Figure 3 Box plots of pleural effusion DNA fragments, integrity index and mesothelin concentrations in subjects with effusions due to
benign aetiology, other cancers and mesothelioma. DNA fragment values were determined by quantitative PCR for ALU (a) 115bp fragment
and (b) a 247bp fragment. The DNA integrity index (c) was defined as the ratio of ALU 247/ALU 115 fragment levels. Mesothelin values (d) were
determined by ELISA. Mann-Whitney U test to was used to assess for any differences in comparison to benign effusions and p values <0.05 were
deemed significant.
Sriram et al. BMC Cancer 2012, 12:428 Page 6 of 12
http://www.biomedcentral.com/1471-2407/12/428Serum
Serum DNA fragment analysis results are provided in
Table 5. There was no difference in serum ALU 115
(median, 234.4 ng/mL vs. 695.4 ng/mL, p=0.599)
(Figure 4a), ALU 247 (median, 226.1 ng/mL vs. 330.2
ng/mL, p=0.968) (Figure 4b) or DNA integrity index
(median, 0.9 vs. 0.9, p=0.461) (Figure 4c) between MPE
and benign effusions.
There was no correlation between pleural fluid and
serum DNA fragments or integrity index [Spearman’s
rho, ALU 115, -0.023 (p=0.852), ALU 247, -0.009
(p=0.943); integrity index, -0.019 (p=0.876)].
Mesothelin levels (pleural and serum)
Mesothelin was measured on 75 pleural fluid and 65
serum samples. There was insufficient serum for
mesothelin testing in 10 subjects. Subjects with meso-
thelioma, in comparison to subjects with benign effu-
sions, had significantly higher pleural fluid mesothelin(median 38 nM vs. 4.6 nM, p<0.001) (Figure 3d) and
serum mesothelin levels (median, 2.0 nM vs. 1.0 nM,
p<0.001) (Figure 4d). In the subjects with mesothelioma,
there was a significant correlation between the serum
and pleural fluid mesothelin levels (Spearman’s rho =
0.632, p<0.001) (Figure 5).
Diagnostic utility of DNA integrity index and mesothelin
To determine the diagnostic utility of pleural effusion
DNA integrity index we calculated its sensitivity and spe-
cificity using ROC analysis (Table 6). The area under the
ROC curve for pleural effusion DNA integrity index was
0.766 (95% CI 0.646 – 0.866) (Figure 6a). We used a speci-
ficity threshold of 90% to compare the utility of pleural
fluid DNA integrity index, pleural fluid mesothelin, and
serum mesothelin in differentiating MPE from benign
effusions. Pleural fluid DNA integrity index (cut-off level
of 1.02) pleural fluid mesothelin (cut-off: 12.72 nM) and
serum mesothelin (cut-off: 1.32 nM) distinguished MPE










































Pleural fluid cytology 0.082
Negative/Equivocal 0.90
(n = 46) (0.75 – 1.12)
Positive 1.12
(n = 29) (0.75 – 1.56)
*p-value-Mann-Whitney U test comparing diagnoses with benign effusions.
Sriram et al. BMC Cancer 2012, 12:428 Page 7 of 12
http://www.biomedcentral.com/1471-2407/12/428from benign effusions with sensitivity of 57%, 37% and
44% respectively. If cytology and raised pleural fluid DNA
integrity index (>1.02) were considered together, the two
tests showed complementarity increasing the sensitivity to
81% while maintaining a specificity of 87% in discriminat-
ing MPE from benign effusions. All of the three pleural ef-
fusion samples with false positive DNA integrity index
were due to inflammatory pleuritis.
We also evaluated the ability of pleural fluid DNA in-
tegrity index and mesothelin to distinguish mesotheli-
oma from benign effusions (Figure 6b). Here we found
that serum mesothelin provided the highest area under
the ROC curve (0.94, 95% CI 0.87-1.00) followed by
pleural fluid mesothelin (0.89, 95% 0.77-1.00) and
pleural effusion DNA integrity index (0.82, 95% CI 0.68-
0.97). Similarly, at a specificity of 90%, pleural fluid
DNA integrity index (cut-off level of 1.06) pleural fluid
mesothelin (cut-off: 12.91 nM) and serum mesothelin
(cut-off: 1.34 nM) distinguished MPE from benign effu-
sions with a sensitivity of 75% each respectively. When
cytology, raised DNA integrity index and raised
mesothelin were considered, the sensitivity increasedfrom 31% for cytology alone to 81% (cytology plus DNA
integrity index), 94% (cytology plus pleural fluid
mesothelin) and 100% (cytology plus serum mesothelin).
However the specificity decreased from 100% (cytology
alone) to 70% for cytology plus pleural fluid mesothelin
and 74% for cytology plus serum mesothelin, while it
remained 87% for cytology plus DNA integrity index.
In subjects with cytology negative pleural effusions
(n=46), MPE was eventually diagnosed in 23 (11 with
mesothelioma, 8 with lung cancer, 2 with lymphoma and
2 with other cancers) (i.e. positive pleural tissue biopsy
or disseminated malignancy with no alternative explan-
ation for the effusion.). Serum mesothelin was available
in 37 cytology negative subjects. Pleural fluid DNA in-
tegrity index was increased in 13 subjects (sensitivity
57%, specificity 87%, 81% PPV and 67% NPV), pleural
fluid mesothelin was increased in 11 subjects (sensitivity
61%, specificity 84%, 78% PPV and 70% NPV) and serum
mesothelin was raised in 11 subjects (sensitivity 48%,
specificity 83%, PPV 73% and 61% NPV).
Discussion
In this translational study, we evaluated the diagnostic
utility of cfDNA fragments, DNA integrity index and
mesothelin in the 75 matched pleural effusion and serum
samples and found that pleural fluid DNA integrity index
is higher in MPE (mesothelioma and other malignancies)
compared to benign effusions. Importantly DNA integrity
index had diagnostic utility in detecting MPE even in cy-
tology negative effusions. In contrast, the diagnostic utility
of pleural effusion and serum mesothelin was limited to
mesothelioma but not non-mesothelioma MPEs.
It has been widely reported that total cfDNA in the
plasma and serum is higher in cancer patients compared
to healthy controls and may serve as a potential diagnos-
tic biomarker for solid organ malignancies [9,15-20].
However the diagnostic utility of total cfDNA in plasma
and serum for lung cancer has been questioned since
the total cfDNA in of patients with non-malignant lung
disease is not significantly different from that of lung
cancer patients [18,21,22]. Additionally there is consider-
able variability in the reported values of total cfDNA in
cancer patients, patients with non-malignant illnesses
and healthy controls, limiting utility as a diagnostic bio-
marker [9]. Previous reports have demonstrated that
cfDNA is 4-6 fold higher in serum compared to plasma
[23] and maybe a better biological specimen to screen
for cfDNA in malignancy [13]. Hence we used matched
serum as a reference comparator to pleural fluid in
evaluating the utility of cfDNA and DNA integrity
index in diagnosing malignancy. An alternative approach
to distinguish malignant from benign effusions has
been to evaluate the utility of quantitative and qualita-
tive tumour-specific alterations, such as microsatellite































































































*p-value-Mann-Whitney U test comparing diagnoses with benign effusions.
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http://www.biomedcentral.com/1471-2407/12/428alterations in effusion DNA [24-28]. Economidou et al.
studied patients with malignant (n=26) and benign
(n=22) effusions and found that microsatellite instability
and loss of heterozygosity in DNA from pleural fluid and
blood were not diagnostically useful [27]. Conversely,
Benlloch et al [24] and Chan et al [25] demonstrated that
pleural effusion total DNA was significantly higher in
MPE compared to benign effusions. However, in the
study by Benlloch et al, all parapneumonic effusions were
excluded from analysis and MPEs were compared pre-
dominantly to transudate effusions [24]. Chan et al. did
not exclude parapneumonic effusions and found that
MPEs had higher total DNA compared to both benign
transudate effusions and infective effusions [25]. How-
ever they also found that while MPE total DNA in
pleural fluid is significantly higher compared to transu-
date effusions (p<0.0001), it was less robustly significant
compared to infective effusions (p=0.048) [25]. Addition-
ally, in the group of infective effusions, the majority
(82%) was due to tuberculosis, a subgroup that is not
represented in our study.
Recently several studies have showed that in com-
parison to healthy controls, serum DNA integrity index
is higher in breast tumours [29] and prostate tumours
[30]. and plasma of head and neck tumours [31],
naso-pharyngeal carcinoma [32] and rectal cancer [33].
In contrast we did not find a difference in serum
DNA integrity index between subjects with MPE and
benign effusions. This is most likely because of oursubjects with inflammatory pleuritis and parapneumo-
nic effusions accounted for 35% and 17% of the benign
effusion cohort. Our findings are consistent with the
findings of Schmidt et al, who also did not find a dif-
ference in the serum DNA integrity index of lung can-
cer patients compared to those with non-malignant
lung disease [34]. This is most likely due to the release
of increased quantities of DNA into the blood from
both apoptotic and necrotic cells in severe inflamma-
tory processes [35].
To our knowledge, only one other study by Salani
et al, has evaluated the diagnostic utility of DNA integ-
rity index in effusions [26]. They measured the integrity
index of cyclin E, a gene frequently amplified in ovarian
carcinoma in ascites and pleural effusions. This study
demonstrated that cyclin E assay was specific to ovarian
carcinomas, thereby limiting its usefulness as a diagnos-
tic test for all MPEs. In our study we used ALU repeats
to measure pleural effusion DNA integrity index, since
ALU repeats are ubiquitous and the ALU qPCR assay
has previously been validated in several different malig-
nancies [13,29,33,36].
Cytology remains the diagnostic standard for evaluat-
ing pleural effusion samples. However it is can be diffi-
cult to establish a diagnosis of MPE in subjects with
cytology-negative effusions, since in such circumstances
diagnosis requires invasive pleural biopsy tests, such
as thoracoscopy. We found that when combined with
cytology, pleural fluid DNA integrity index substantially















































































p =0.198 p =0.667 
p =0.408 p <0.001 
p =0.986 p =0.726 
p =0.585 p =0.951 
Figure 4 Box plots of serum DNA fragments, integrity index and mesothelin concentrations in subjects with effusions due to benign
aetiology, other cancers and mesothelioma. DNA fragment values were determined by quantitative PCR for ALU (a) 115bp fragment and
(b) a 247bp fragment. The DNA integrity index (c) was defined as the ratio of ALU 247/ALU 115 fragment levels. Mesothelin values (d) were
determined by ELISA. Mann-Whitney U test to was used to assess for any differences in comparison to benign effusions and p values <0.05
were deemed significant.
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http://www.biomedcentral.com/1471-2407/12/428increased the ability to distinguish benign effusions from
MPE (sensitivity 81% vs. 55%) and mesothelioma (sensi-
tivity. 81% vs. 31%). Importantly, almost a third of false
positive pleural fluid DNA integrity index results were
due to parapneumonic effusions. Additionally, we
showed that in cytology negative effusions, elevated
pleural fluid DNA integrity index had 81% PPV. Hence
pleural fluid DNA integrity index provides valuable add-
itional information to pleural fluid cytology, particularly
in subjects with either inconclusive or “suspicious” cy-
tology results. This may have clinical implications since
an elevated pleural fluid DNA integrity index in a
cytology-negative subjects should be prioritized to
undergo thoracoscopy.
Our study included subjects with mesothelioma (31%
of subjects with MPE), a subgroup that was present in
only 0-3% of other studies that have studied total DNAin effusions [24–26]. It is now important to identify ac-
curate diagnostic biomarkers for mesothelioma since it
is increasing in incidence, with a peak predicted to occur
between 2014 to 2021 [37]. Consistent with previous
studies, we found that pleural effusion and serum
mesothelin has diagnostic utility for mesothelioma
[7,8,38]. However a weakness of our findings is that
serum mesothelin results could not be obtained in 13%
(10/75) of study subjects. Nonetheless, our data demon-
strate that pleural fluid DNA integrity index is compar-
able in sensitivity to pleural fluid and serum mesothelin
in diagnosing mesothelioma.
There are certain limitations to consider before the
results of our study can be applied to other patient popu-
lations. Firstly, while our study has found that DNA integ-
rity has utility in distinguishing MPEs from benign
effusions, it should be noted the method used for
Figure 5 Dot plot representing the correlation of mesothelin
(log values) concentration of pleural effusion and serum in
study subjects (n=74).
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http://www.biomedcentral.com/1471-2407/12/428measuring DNA integrity in our study is one of several
others that have been reported in the literature [12]. In
this study, we have used the ratio of the longer DNA frag-
ments to the shorter DNA fragments to measure DNA in-
tegrity (ALU 247/115), as described by Umetani et al [13].
This methodology has since been used by other investiga-
tors to measure DNA integrity in the serum of breast can-
cer patients [36] and plasma of rectal cancer patients [33].
Most recently, Agostini et al found that DNA integrity
(ALU 247/115) in the plasma of patients with rectal
adenocarcinoma (n=67, median, IQR25-75 1.1 (0.7-1.9))
compared to healthy control subjects (n=35, median,
IQR25-75; 0.1 (0.0 – 0.4)) [33]. The findings of DNA in-
tegrity in malignancy are similar to our study where the
median DNA integrity in serum 0.9 (0.5-1.3). Interestingly,
the serum DNA integrity index in our cohort of subjects
with benign effusions was also relatively high and not sig-
nificantly different from subjects with MPEs (median,
IQR25-75; 0.9, 0.5-1.0). This is not unexpected since our
‘control’ population were not normal healthy volunteers
but subjects with non-malignant pulmonary diseases. Sec-
ondly the different studies have not only used other meth-








DNA Integrity index cut-off: 1.02 0.766 (0.646 - 0.866) 57
Pleural fluid mesothelin cut-off: 12.72 nM 0.620 (0.480-0.759) 37
Serum mesothelin Cut-off: 1.34 nM 0.674 (0.546-0.802) 44protocols to process and extract DNA from blood [12].
Recently Fleischhacker et al found that significantly differ-
ent amounts of absolute DNA values were obtained from
plasma using different DNA isolation methods [39]. In-
deed Jung et al, note that the considerable heterogeneity
in preanalytical and analytical factors considerably deter-
mine the interpretation of cfDNA and DNA integrity
studies in malignancy, thereby limiting the translation of
this test into clinical practice [12]. Hence, despite exten-
sive research into the utility of cfDNA and DNA integrity
index as diagnostic and prognostic biomarkers in malig-
nancy, the methodological discrepancies have dictated that
the tests have remained as research tools. Thirdly, another
limitation of our study relates to the relatively small num-
ber of subjects evaluated and the casemix of pleural effu-
sion diagnoses, particularly the relatively high proportion
of mesothelioma subjects (31%), derived at a single Aus-
tralian thoracic tertiary referral centre. It is well recognised
that the distribution of aetiologies of pleural effusions (in-
cluding MPEs) vary considerably according to geographic
location [40]. Further validation will be needed to address
issues of generalisability and applicability. Finally, another
restriction of our study is that the DNA extracted from a
mixture of various types of cells present in pleural fluid
(tumour cells, mesothelial cells, white blood cells). The in-
fluence of non-tumour cells on DNA fragments is cur-
rently not known and will also need to be evaluated. For
these reasons, our findings should be interpreted as a pilot
study, albeit with results suggesting that pleural fluid
DNA integrity index is a promising diagnostic biomarker
for MPEs. The results require confirmation in prospect-
ively conducted multicentre studies with sufficient atten-
tion paid to the methodological variations common in
cfDNA and DNA integrity index research before they can
be incorporated into clinical decision-making algorithms.
Conclusions
Our results indicate that pleural fluid DNA integrity
index is a promising diagnostic biomarker for MPEs.
The increased sensitivity over conventional cytological
examination may assist clinicians in directing patients
for further examinations, such as thoracoscopy or to
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Figure 6 Receiver operator characteristic analysis of pleural effusion DNA integrity index, pleural effusion mesothelin and serum
mesothelin to evaluate the diagnostic accuracy of malignant pleural effusions (a) and mesothelioma (b).
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http://www.biomedcentral.com/1471-2407/12/428integrity index maybe a valuable adjunctive test when
evaluating subjects presenting with pleural effusions, es-
pecially when cytology is inconclusive or suspicious.
These findings warrant confirmation and consequently,
we are planning a large-scale prospective study to evalu-
ate the clinical utility of pleural fluid DNA integrity
index and mesothelin as initial tests in patients with
pleural effusions. The introduction of pleural fluid DNA
integrity index, a minimally invasive and technically sim-
ple test can provide additional information that may re-
duce the need for thoracoscopy, an invasive test with
associated patient-related morbidity.
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